19:08 , Feb 21, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting FER in combination with paclitaxel could help treat ovarian cancer. In five human ovarian cancer cell lines, a tool compound FER inhibitor plus paclitaxel decreased...
17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
19:01 , Oct 24, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; pancreatic cancer In vitro , cell culture and mouse studies identified a piperidinylimidazothiadiazole-based FER inhibitor that could help treat colorectal and pancreatic cancers. Screening of a small molecule library in a cell-based...
07:00 , Oct 19, 2009 |  BioCentury  |  Finance

Ebb & Flow

Armed with two Special Protocol Agreements from FDA, Amarin Corp. (NASDAQ:AMRN) has been able to resurrect its fortunes by convincing investors that a compound that disappointed in its original indication of Huntington's disease deserves a...
07:00 , Aug 4, 2008 |  BC Week In Review  |  Clinical News

Ferumoxytol: Phase II start

This half, AMAG will begin an open-label, U.S. Phase II trial (FER-PAD-001) in about 100 patients who will receive a digital subtraction angiography (DSA), a non-contrast MR angiogram and a ferumoxytol-enhanced MRI. AMAG Pharmaceuticals Inc....